Today's story
AstraZeneca invests $2 billion in Summit cancer drug partnership
AstraZeneca will invest $2 billion in Summit Therapeutics convertible preferred shares, with Summit stock up more than 17% after-hours ahead of a November 14 FDA decision on ivonescimab.
Business · 11 sources · Sep 29, 2026Read it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About AstraZeneca
AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Everything about AstraZeneca →- Country
- United Kingdom, Sweden
- Headquarters
- Cambridge, Cambridge Biomedical Campus
- Inception
- 1913
- Website
- http://www.astrazeneca.com/